A clinical trial in relapsed T-ALL showed that mitoxantrone, a type II topoisomerase inhibitor that also inhibits USP11, increased progression-free and overall survival compared with idarubicin (71, 72). This evidence concerns the gene USP11 and acute lymphoblastic leukemia.